Joseph Panetta of BIOCOM discusses state life sciences industry’s responses to COVID-19, $5B CIRM referendum, and updated economic impact report
Joseph Panetta, President and CEO of BIOCOM, discusses two challenges to California’s life science industry: The development of new drugs and vaccines against COVID-19, and the voter referendum set for November on whether to extend state bonding authority for the state’s stem cell agency, the California Institute for Regenerative Medicine. BIOCOM recently released a report highlighting the economic impact of the state’s life science industry. [Alex Philippidis]
California’s life science industry faces some formidable headwinds: The development of new drugs and vaccines against COVID-19, and the voter referendum set for November on whether to extend state bonding authority for the state’s stem cell agency, the California Institute for Regenerative Medicine. BIOCOM recently released a report highlighting the economic impact of the state’s life science industry . . .
